Professor of Neuroimmunology. Has been doing MS research in Cambridge since 1994. He is also a consultant neurologist. With Alastair Compston, he was very involved in the development of alemtuzumab as a treatment of MS.
Jonathon is a senior Paediatric Neurology registrar in Cambridge. He embarked upon a 3-year Action Medical Research and British Paediatric Neurology Association Research Training Fellowship in November 2022, in which he will investigate remyelination in paediatric onset multiple sclerosis, and study for a PhD.
Chris is a junior doctor, starting Neurology and Internal Medicine training in Summer 2021. He did his PhD with Robin Franklin at the Cambridge Stem Cell Institute, investigating the role of the gut-brain axis during CNS remyelination (McMurran CE et al., Proc Natl Acad Sci U S A. 2019 PMID: 31740610). Chris is interested in how the brain’s capacity to repair declines with age, and developing interventions to reverse this. As a post-doctoral researcher in the Coles group, he is exploring how chronological and biological age affect remyelination in clinical datasets. He is also involved in setting up the CCMR Two trial, in which one of the treatment drugs – metformin – has rejuvenating effects on myelin repair in preclinical studies.